Inclusion Criteria:

• Visual acuity 20/25 to 20/40.
• Epiretinal membrane (ERM) must be thought to be the primary cause of vision loss.
• ERM meeting the following criteria.
• Symptoms of visual loss and/or distortion (and in the opinion of the investigator, the ERM is contributing to the participant's symptoms); either new or worsening in the past 24 months.
• Epiretinal membrane involving or altering the central 3 mm of the macula on optical coherence tomography (OCT).
• Distortion within the central subfield by ERM on OCT.
• Immediate vitrectomy not required (investigator and participant are willing to wait at least 4 weeks to see if vision remains stable without having to proceed to vitrectomy).
• No known medical problems that will be a contraindication to surgery.

Exclusion Criteria:

• Secondary ERM due to retinal vascular disease, vitreous hemorrhage, retinal detachment, inflammatory disease, or associations other than vitreous syneresis, retinal break, or posterior vitreous detachment.
• History of vitreous hemorrhage is permitted provided the vitreous hemorrhage did not cause the ERM in the investigator's opinion.
• Prior retinal tears treated with laser or cryosurgical retinopexy are permitted provided the laser or cryosurgical retinopexy is completed at least one month prior to randomization.
• Prior intraocular surgery (except uncomplicated cataract extraction).
• Cataract extraction within prior 3 months.
• History of diabetic macular edema (DME), retinal vein occlusion (RVO), or uveitis.
• Past or current macular hole or degenerative lamellar macular hole.
• Vitreomacular traction within 1,500 microns of the foveal center.
• Central serous chorioretinopathy.
• Nonproliferative diabetic retinopathy or worse (diabetic retinopathy severity > 20).

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 9/1/22. Questions regarding updates should be directed to the study team contact.